MedTrace Logo

Taurine Eye Drops May Prevent the Progression of Cataract

NCT06639711 · Status: ACTIVE_NOT_RECRUITING · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 50

Last updated 2024-12-09

No results posted yet for this study

Summary

The aim of the current intervention study is to determine the effectiveness of taurine containing eye drops (available under brand name VIZILOTON) to prevent the progression of grade I and II senile cataract.

This study could answer:

* Dose continuous use of taurine-containing eye drops could prevent further deterioration of vision in mild cases of cataract?
* The acceptance/ compliance of participants to taurine-containing eye drops.
* Could long-term use of taurine-containing eye drops cause adverse effect(s)?

Participants will:

* Take taurine-containing eye drops (VIZILOTON eye drops) 4 times a day for one year.
* Visit eye clinic every 3 months for assessment and visual examination.
* Keep notes for their symptoms and their adherence to treatment.

Conditions

  • Cataract

Interventions

DRUG

Taurine

Taurine-containing eye drops (VIZILOTON) are applied 4 times daily for a period of one year

Sponsors & Collaborators

  • University Of Anbar

    lead OTHER

Study Design

Allocation
NA
Purpose
PREVENTION
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-07-10
Primary Completion
2024-12-20
Completion
2024-12-20

Countries

  • Iraq

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06639711 on ClinicalTrials.gov